Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma

Just as the ball got rolling on Medicare’s new negotiation powers, the U.S. underwent a radical change in leadership, leaving the drug pricing fight ostensibly in the Trump administration’s hands. Now the question is: Where does it go from here?

From the first…